Clinical Trial Detail

NCT ID NCT03664024
Title Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Merck Sharp & Dohme Corp.
Indications

non-small cell lung carcinoma

Therapies

Pemetrexed + Pembrolizumab

Carboplatin + Pembrolizumab + Pemetrexed

Cisplatin + Pembrolizumab + Pemetrexed

Age Groups: adult senior

Additional content available in CKB BOOST